Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | ACE | P12821 | 6/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497475 | 0.93 | LTA4H (0.66) | LTA4HMMEOPRM1OPRD1OPRK1 | |
| SCHEMBL3497478 | 0.93 | LTA4H (0.66) | LTA4HMMEOPRM1OPRD1OPRK1 | |
| SCHEMBL30051506 | 0.92 | LTA4H (0.72) | LTA4HMMEOPRM1OPRD1OPRK1 | |
| SCHEMBL30619402 | 0.92 | OPRM1 (0.58) | LTA4HACECAPN1MMEOPRM1 | |
| SCHEMBL30872253 | 0.91 | BACE1 (0.65) | OPRM1OPRD1 | |
| SCHEMBL30051692 | 0.91 | LTA4H (0.67) | LTA4HACEMME | |
| SCHEMBL30051113 | 0.91 | OPRD1 (0.60) | LTA4HACEMMEOPRM1OPRD1 | |
| SCHEMBL31720963 | 0.90 | CTSD (0.58) | LTA4H | |
| SCHEMBL30538859 | 0.90 | NPY4R (0.57) | CAPN1OPRM1OPRD1OPRK1 | |
| SCHEMBL11151397 | 0.90 | ACE (0.58) | LTA4HACECAPN1MMEOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673914-B2 | Peptide therapies for reduction of macular thickening | Allegro Pharmaceuticals, LLC (US) | 2023-06-13 | — | — | US | claimed |
| US-11666625-B2 | Pharmaceutical compositions and preparations for administration to the eye | Allegro Pharmaceuticals, LLC (US) | 2023-06-06 | — | — | US | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20230090311-A1 | SELF-ASSEMBLING, SELF-ADJUVANTING SYSTEM FOR DELIVERY OF VACCINES | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-03-23 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| EP-4087606-A1 | SELF-ASSEMBLING, SELF-ADJUVANTING SYSTEM FOR DELIVERY OF VACCINES | The University of Queensland (AU) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673914-B2 | Peptide therapies for reduction of macular thickening | ITGB3, ITGB5, ITGAV | LTA4H 509/4885ACE 3189/4885CAPN1 2291/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | LTA4H 3533/4885ACE 1190/4885CAPN1 2111/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | LTA4H 1299/4885ACE 486/4885CAPN1 1210/4885 |
| US-20230090311-A1 | SELF-ASSEMBLING, SELF-ADJUVANTING SYSTEM FOR DELIVERY OF VACCINES | LY96, TLR3, STING1 | LTA4H 551/4885ACE 1451/4885CAPN1 3273/4885 |
| US-11666625-B2 | Pharmaceutical compositions and preparations for administration to the eye | GCG, HGFAC, ARGLU1 | LTA4H 1530/4885ACE 2397/4885CAPN1 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.